TN2011000053A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number: TN2011000053A1
Authority: TN; Tunisia
Prior art keywords: organic compounds; compounds; phosphatidylinositol; kinase; substituents
Prior art date: 2008-09-10

Application number

TN2011000053A

Other languages

English (en)

Inventor

Giorgio Caravatti

Pascal Furet

Robin Alec Fairhurst

Vito Guagnano

Patricia Imbach

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-10

Filing date

2011-01-31

Publication date

2012-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40350060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-01-31 Application filed by Novartis Ag filed Critical Novartis Ag

2012-09-05 Publication of TN2011000053A1 publication Critical patent/TN2011000053A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)

TN2011000053A 2008-09-10 2011-01-31 Organic compounds TN2011000053A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08164104		2008-09-10
US9667408P	2008-09-12	2008-09-12
PCT/EP2009/061644 WO2010029082A1 (fr)	2008-09-10	2009-09-08	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2011000053A1 true TN2011000053A1 (en)	2012-09-05

Family

ID=40350060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000053A TN2011000053A1 (en)	2008-09-10	2011-01-31	Organic compounds

Country Status (50)

Country	Link
US (4)	US8227462B2 (fr)
EP (1)	EP2331537B1 (fr)
JP (1)	JP5486601B2 (fr)
KR (1)	KR101290844B1 (fr)
CN (1)	CN102149711B (fr)
AR (2)	AR073369A1 (fr)
AU (1)	AU2009290904B2 (fr)
BR (1)	BRPI0918750B8 (fr)
CA (1)	CA2734819C (fr)
CL (1)	CL2011000504A1 (fr)
CO (1)	CO6351738A2 (fr)
CR (1)	CR20110059A (fr)
CU (1)	CU24000B1 (fr)
CY (2)	CY1117078T1 (fr)
DK (1)	DK2331537T3 (fr)
DO (1)	DOP2011000070A (fr)
EA (1)	EA018863B1 (fr)
EC (1)	ECSP11010880A (fr)
ES (1)	ES2560673T3 (fr)
FI (1)	FIC20200046I1 (fr)
GE (1)	GEP20135991B (fr)
HN (1)	HN2011000699A (fr)
HR (1)	HRP20160014T1 (fr)
HU (2)	HUE025884T2 (fr)
IL (1)	IL210976A (fr)
JO (1)	JO3121B1 (fr)
LT (1)	LTC2331537I2 (fr)
LU (1)	LUC00186I2 (fr)
MA (1)	MA32604B1 (fr)
ME (1)	ME01284B (fr)
MX (1)	MX2011002597A (fr)
MY (1)	MY151556A (fr)
NI (1)	NI201100049A (fr)
NL (1)	NL301071I2 (fr)
NO (1)	NO2020037I1 (fr)
NZ (1)	NZ590754A (fr)
PA (1)	PA8841901A1 (fr)
PE (1)	PE20110796A1 (fr)
PL (1)	PL2331537T3 (fr)
PT (1)	PT2331537E (fr)
RS (1)	RS54476B1 (fr)
SI (1)	SI2331537T1 (fr)
SM (1)	SMP201100019B (fr)
SV (1)	SV2011003853A (fr)
TN (1)	TN2011000053A1 (fr)
TW (1)	TWI453206B (fr)
UA (1)	UA104147C2 (fr)
UY (1)	UY32096A (fr)
WO (1)	WO2010029082A1 (fr)
ZA (1)	ZA201100699B (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR044519A1 (es) *	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
CA2729914A1 (fr)	2008-07-11	2010-01-14	Novartis Ag	Combinaison de (a) un inhibiteur de phosphoinositide 3-kinase et de (b) un modulateur de voie ras/raf/mek
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) *	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
CN103200943A (zh) *	2010-11-08	2013-07-10	诺华有限公司	2-甲酰胺环氨基尿素衍生物在治疗egfr依赖性疾病或对靶向egfr家族成员的药剂有获得性耐受性的疾病中的应用
AU2015203865B2 (en) *	2010-11-08	2016-11-03	Novartis Ag	Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
UA112539C2 (uk) *	2011-03-03	2016-09-26	Новартіс Аг	Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
EP2701703A1 (fr) *	2011-04-25	2014-03-05	Novartis AG	Association d'un inhibiteur de phosphatidylinositol-3-kinase (pi3k) et d'un inhibiteur de mtor
EP2723733A1 (fr)	2011-06-21	2014-04-30	Novartis AG	Polymorphes du 2-amide-1-({4-méthyl-5-[2-(2,2,2-trifluoro-1,1-diméthyl- éthyl)pyridin-4-yl]-thiazol-2-yl}-amide d'acide (s)-pyrrolidine-1,2-dicarboxylique
EA030465B1 (ru)	2011-07-01	2018-08-31	Новартис Аг	Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
KR20140072028A (ko) *	2011-08-31	2014-06-12	노파르티스 아게	Pi3k- 및 mek-억제제의 상승작용적 조합물
US20140235630A1 (en) *	2011-09-30	2014-08-21	Beth Israel Deaconess Medical Center, Inc.	Compositions and methods for the treatment of proliferative diseases
RU2624493C2 (ru) *	2011-10-14	2017-07-04	Новартис Аг	2-КАРБОКСАМИД ЦИКЛОАМИНО ПРОИЗВОДНЫЕ МОЧЕВИНЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ Hsp90 ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
PH12014500897A1 (en)	2011-10-28	2019-10-07	Novartis Ag	Method of treating gastrointestinal stromal tumors
BR112014010233A2 (pt) *	2011-11-02	2017-04-18	Novartis Ag	derivados de 2-carboxamida cicloamino ureia para uso no tratamento de doenças dependentes de vegf
CA2865071C (fr)	2012-02-22	2020-06-23	Sanford-Burnham Medical Research Institute	Composes sulfonamides et leurs utilisations en tant qu'inhibiteurs de tnap
SG10201608001RA (en) *	2012-03-29	2016-11-29	Novartis Ag	Pharmaceutical diagnostic
AU2013239624A1 (en) *	2012-03-30	2014-10-02	Novartis Ag	Compounds for use in the treatment of neuroblastoma, Ewing's Sarcoma or rhabdomyosarcoma
KR20160027217A (ko)	2012-05-23	2016-03-09	에프. 호프만-라 로슈 아게	내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8980259B2 (en)	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
UA115786C2 (uk)	2012-08-07	2017-12-26	Новартіс Аг	ФАРМАЦЕВТИЧНА КОМБІНАЦІЯ, ЩО МІСТИТЬ ІНГІБІТОР B-Raf, ІНГІБІТОР EGFR ТА, НЕОБОВ'ЯЗКОВО, ІНГІБІТОР РІ3K-?
MX369518B (es) *	2012-08-16	2019-11-11	Novartis Ag	Combinacion de inhibidor de p13k e inhibidor de c-met.
CN104661681B (zh) *	2012-09-20	2018-07-03	诺华股份有限公司	包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合
JP6316835B2 (ja) *	2012-11-16	2018-04-25	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	３−アミノシクロペンタンカルボキサミド誘導体
EP3251673A1 (fr)	2012-12-13	2017-12-06	IP Gesellschaft für Management mbH	Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer
MX361136B (es)	2013-01-23	2018-11-28	Astrazeneca Ab	Compuestos quimicos.
CN105339001A (zh)	2013-03-15	2016-02-17	基因泰克公司	治疗癌症和预防癌症耐药性的方法
JP6449234B2 (ja) *	2013-03-21	2019-01-09	ノバルティスアーゲー	併用療法
SG11201507720PA (en) *	2013-04-05	2015-10-29	Sanofi Sa	Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
EP3003377A1 (fr)	2013-05-31	2016-04-13	Novartis AG	Polythérapie comprenant un inhibiteur pi3k-alpha et un inhibiteur de kinase fgfr pour traiter le cancer
BR112015030664A2 (pt)	2013-06-11	2017-07-25	Novartis Ag	combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos
EP3010505A1 (fr)	2013-06-18	2016-04-27	Novartis AG	Combinaisons pharmaceutiques
CN105611928A (zh)	2013-08-08	2016-05-25	诺华股份有限公司	Pim激酶抑制剂组合
DK3033086T3 (da)	2013-08-14	2022-01-03	Novartis Ag	Kombinationsterapi til behandling af cancer
US10570204B2 (en)	2013-09-26	2020-02-25	The Medical College Of Wisconsin, Inc.	Methods for treating hematologic cancers
MX378409B (es)	2013-12-06	2025-03-10	Novartis Ag	Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
KR20160101027A (ko)	2014-01-15	2016-08-24	노파르티스 아게	제약 조합물
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20170165246A1 (en)	2014-02-11	2017-06-15	Novartis Ag	Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
WO2015138920A1 (fr)	2014-03-14	2015-09-17	Novartis Ag	Molécules d'anticorps anti-lag-3 et leurs utilisations
EP3191127A1 (fr)	2014-09-13	2017-07-19	Novartis AG	Polythérapie par les inhibiteurs de l'egfr
EP3200775B1 (fr)	2014-10-03	2019-11-20	Novartis AG	Polythérapies
MX2017004359A (es)	2014-10-03	2017-06-23	Novartis Ag	Composiciones farmaceuticas que comprenden alpelisib.
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20171067A1 (es)	2014-10-14	2017-07-24	Novartis Ag	Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CN104844589B (zh) *	2014-12-26	2018-04-20	中国科学院合肥物质科学研究院	一种pi3k激酶抑制剂
HK1247089A1 (zh)	2015-03-10	2018-09-21	Aduro Biotech, Inc.	用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
WO2016151501A1 (fr)	2015-03-25	2016-09-29	Novartis Ag	Combinaisons pharmaceutiques
CA2981159A1 (fr)	2015-06-29	2017-01-05	F. Hoffmann-La Roche Ag	Methodes de traitement avec du taselisib
CN112047960B (zh)	2015-07-02	2024-08-02	豪夫迈·罗氏有限公司	苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
EP3316902A1 (fr)	2015-07-29	2018-05-09	Novartis AG	Polythérapies comprenant des molécules d'anticorps contre tim -3
WO2017019894A1 (fr)	2015-07-29	2017-02-02	Novartis Ag	Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
CN114272371A (zh)	2015-07-29	2022-04-05	诺华股份有限公司	包含抗pd-1抗体分子的联合疗法
EP3380097A2 (fr) *	2015-08-28	2018-10-03	Novartis AG	Combinaison pharmaceutique comprenant (a) l'inhibiteur au pi3k isoforme-alpha spécifique alpelisib (byl719) et (b) un inhibiteur à akt, de préférence mk-2206, afuresertib ou uprosertib, et son utilisation dans le traitement/la prévention du cancer
JP2018526377A (ja)	2015-08-28	2018-09-13	ノバルティスアーゲー	がんを治療するための、任意にｐｉ３ｋ阻害剤のｂｙｌ７１９を更に含む、ｃｄｋ４／６阻害剤のｌｅｅ０１１とｍｅｋ１／２阻害剤トラメチニブの組み合わせ物
WO2017037579A1 (fr)	2015-08-28	2017-03-09	Novartis Ag	Inhibiteurs de mdm2 et combinaisons de ceux-ci
CN108348514A (zh)	2015-08-28	2018-07-31	诺华股份有限公司	含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
CN108348513A (zh)	2015-08-28	2018-07-31	诺华股份有限公司	用于治疗或预防癌症的ribociclib与达拉菲尼的组合
CN108348611A (zh)	2015-08-28	2018-07-31	诺华股份有限公司	使用pi3k抑制剂和mdm2抑制剂的联合疗法
TW201726140A (zh)	2015-09-17	2017-08-01	瑞典商阿斯特捷利康公司	治療癌症之新型生物標記及方法
CN105294546B (zh) *	2015-10-29	2017-12-08	天津市斯芬克司药物研发有限公司	一种吡啶化合物及其制备方法
JP2018532750A (ja)	2015-11-02	2018-11-08	ノバルティスアーゲー	ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
CN108697791B (zh)	2015-11-03	2022-08-23	詹森生物科技公司	特异性结合pd-1的抗体及其用途
WO2017093905A1 (fr)	2015-12-03	2017-06-08	Novartis Ag	Traitement du cancer avec un inhibiteur de pi3k chez un patient présélectionné comme ayant une mutation de pik3ca dans l'adntc
MX2018007423A (es)	2015-12-17	2018-11-09	Novartis Ag	Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
EP3507367A4 (fr)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
WO2018060833A1 (fr)	2016-09-27	2018-04-05	Novartis Ag	Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
WO2018092064A1 (fr)	2016-11-18	2018-05-24	Novartis Ag	Combinaisons d'inhibiteurs de mdm2 et d'inhibiteurs de bcl-xl
CN106674200B (zh) *	2016-12-21	2019-04-12	西安交通大学	一种含有l-脯氨酰胺片段的化合物及其制备方法和应用
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (fr)	2017-06-22	2020-04-29	Novartis AG	Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
PE20200717A1 (es)	2017-06-22	2020-07-21	Novartis Ag	Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
EP3694511A1 (fr)	2017-10-13	2020-08-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Polythérapie du cancer du pancréas
US12000833B2 (en)	2017-11-23	2024-06-04	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Marker for predicting the sensitivity to PI3K inhibitors
EP3716969A1 (fr)	2017-12-01	2020-10-07	Novartis AG	Combinaison pharmaceutique comprenant du lsz102 et de l'alpésilib
US11465985B2 (en) *	2017-12-08	2022-10-11	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3093445A1 (fr)	2018-03-08	2019-11-28	Incyte Corporation	Composes d'aminopyrazine diol utilises comme inhibiteurs de pi3k-.gamma.
CN110785423B (zh)	2018-05-30	2022-07-26	江苏豪森药业集团有限公司	含三并环类衍生物抑制剂、其制备方法和应用
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en)	2018-05-31	2021-07-15	Novartis Ag	Antibody molecules to cd73 and uses thereof
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
EP3849545A1 (fr) *	2018-09-10	2021-07-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	Procédés de traitement de la neurofibromatose
AU2019355574A1 (en) *	2018-10-05	2021-05-06	Sloan-Kettering Institute For Cancer Research	PI3K inhibitors and uses thereof
EP3903828A4 (fr)	2018-12-21	2022-10-05	Daiichi Sankyo Company, Limited	Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase
EP3971175A4 (fr)	2019-05-13	2022-11-09	Luoxin Healthcare Science and Technology Development (Beijing) Ltd.	Forme cristalline de composé quinazolinone et son procédé de préparation
CN120172965A (zh) *	2019-05-27	2025-06-20	君实润佳(上海)医药科技有限公司	含有稳定重同位素的酰胺官能团的化合物及其应用
WO2021001431A1 (fr)	2019-07-02	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Utilisation d'inhibiteurs sélectifs de pi3ka pour traiter une maladie métastatique chez des patients souffrant de cancer du pancréas
EP3993707A1 (fr)	2019-07-02	2022-05-11	Institut National de la Santé et de la Recherche Médicale (INSERM)	Utilisation d'une imagerie d'élasticité ultrarapide pour la détection de cancers du pancréas
WO2021001427A1 (fr)	2019-07-02	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés de traitement prophylactique du cancer chez des patients souffrant de pancréatite
AU2020311337A1 (en)	2019-07-07	2022-01-20	Olema Pharmaceuticals, Inc.	Regimens of estrogen receptor antagonists
IL320609A (en)	2019-08-26	2025-07-01	Arvinas Operations Inc	Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
WO2021053559A1 (fr)	2019-09-18	2021-03-25	Novartis Ag	Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
US20230014383A1 (en)	2019-11-25	2023-01-19	Shanghai Hansoh Biomedical Co., Ltd.	Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof
CN113045564B (zh) *	2019-12-27	2024-09-20	上海天慈国际药业有限公司	一种阿培利司的制备方法
AU2021244786A1 (en)	2020-03-25	2022-11-03	Risen (Suzhou) Pharma Tech Co., Ltd.	Stable heavy isotopes in amide functional groups and uses thereof
WO2022016420A1 (fr) *	2020-07-22	2022-01-27	罗欣药业(上海)有限公司	Forme cristalline d'un composé quinazolinone, son procédé de préparation et son utilisation
EP4333812A1 (fr)	2021-05-03	2024-03-13	Novartis AG	Formulation d'alpélisib
CN115611883B (zh) *	2021-07-13	2025-03-28	生物岛实验室	一种双环结构的PI3Kα抑制剂及其制备方法和用途
EP4431508A4 (fr) *	2021-11-12	2025-12-31	Biopolar Youtang Guangdong Pharmaceutical Co Ltd	Inhibiteur de drak2, son procédé de préparation et son utilisation
EP4230196A1 (fr)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Composés à utiliser dans le traitement des dystrophinopathies
WO2024089272A1 (fr)	2022-10-28	2024-05-02	Institut National De La Sante Et De La Recherche Medicale	Nouveaux inhibiteurs de la phosphatidylinositol 3-kinase
CN120187416A (zh)	2022-11-11	2025-06-20	阿斯利康(瑞典)有限公司	用于治疗癌症的组合疗法
CN116239591B (zh) *	2023-02-14	2025-09-23	嘉兴大学	一种(4r)-磺酰氨基-l-脯氨酰胺类化合物、制备方法、应用及其药物组合
WO2024206147A1 (fr)	2023-03-24	2024-10-03	Arvinas Operations, Inc.	Schémas posologiques d'agents de dégradation des récepteurs des œstrogènes
CN116987072A (zh) *	2023-07-27	2023-11-03	武汉呈瑞生物医药科技有限公司	化合物及其应用
WO2025181153A1 (fr)	2024-03-01	2025-09-04	F. Hoffmann-La Roche Ag	Utilisation d'inhibiteurs d'atr en combinaison avec des inhibiteurs de pi3k alpha
EP4643858A1 (fr) *	2024-04-29	2025-11-05	Institut National de la Santé et de la Recherche Médicale	Procédés et composition pharmaceutique pour le traitement d'une maladie utérine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4649146A (en)	1983-01-31	1987-03-10	Fujisawa Pharmaceutical Co., Ltd.	Thiazole derivatives and pharmaceutical composition comprising the same
DE3703435A1 (de)	1987-02-05	1988-08-18	Thomae Gmbh Dr K	Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
KR910009934B1 (ko)	1988-04-15	1991-12-06	다이호오 야꾸힌 고오교오 가부시끼가이샤	카르바모일-2-피롤리디논 화합물
US5028726A (en) *	1990-02-07	1991-07-02	The University Of Vermont And State Agricultural College	Platinum amine sulfoxide complexes
US5780653A (en) *	1995-06-07	1998-07-14	Vivorx Pharmaceuticals, Inc.	Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
WO1998027108A2 (fr)	1996-12-16	1998-06-25	Fujisawa Pharmaceutical Co., Ltd.	Nouveaux composes amide
US6187797B1 (en)	1996-12-23	2001-02-13	Dupont Pharmaceuticals Company	Phenyl-isoxazoles as factor XA Inhibitors
JP4515542B2 (ja) *	1997-02-10	2010-08-04	ジェネンテック，インコーポレイテッド	ヒレグリン変異体
AU9648098A (en)	1997-10-27	1999-05-17	Takeda Chemical Industries Ltd.	Adenosine a3 receptor antagonists
EP1087951B9 (fr)	1998-06-18	2006-09-13	Bristol-Myers Squibb Company	Aminothiazole a substituant carbone, inhibiteurs de kinases dependantes de cycline
ATE309241T1 (de)	1999-09-10	2005-11-15	Merck & Co Inc	Tyrosin kinase inhibitoren
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
CN100355751C (zh)	2000-03-29	2007-12-19	西克拉塞尔有限公司	2－取代的4－杂芳基－嘧啶、其组合物及其用途
EP1415987B1 (fr)	2000-10-20	2007-02-28	Eisai R&D Management Co., Ltd.	Composes heteroaromatiques azotes pour le traitement des maladies de cancer
ATE315555T1 (de)	2001-05-11	2006-02-15	Pfizer Prod Inc	Thiazolderivate und ihre verwendung als cdk- inhibitoren
KR100979988B1 (ko)	2001-08-13	2010-09-03	얀센 파마슈티카 엔.브이.	2-아미노-4,5-삼치환 티아졸릴 유도체
WO2003015778A1 (fr)	2001-08-17	2003-02-27	Merck & Co., Inc.	Inhibiteurs de tyrosine kinase
IL161092A0 (en)	2001-09-28	2004-08-31	Cyclacel Ltd	N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds
TWI314928B (en)	2002-02-28	2009-09-21	Novartis A	5-phenylthiazole derivatives and use as pi3 kinase inhibitors
NZ540161A (en)	2002-10-30	2008-03-28	Vertex Pharma	Compositions useful as inhibitors of rock and other protein kinases
US7632858B2 (en)	2002-11-15	2009-12-15	Bristol-Myers Squibb Company	Open chain prolyl urea-related modulators of androgen receptor function
BRPI0406667A (pt) *	2003-01-10	2005-12-20	Threshold Pharmaceuticals Inc	Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
GB0305152D0 (en)	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
AR044519A1 (es) *	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0320197D0 (en) *	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
MXPA06002567A (es)	2003-09-06	2006-09-04	Vertex Pharma	Moduladores de transportadores con casete de union de atp.
RS50521B (sr)	2004-01-12	2010-05-07	Applied Research Systems Ars Holding N.V.	Derivati tiazola i njihova upotreba
WO2006004703A2 (fr) *	2004-06-29	2006-01-12	Amgen Inc.	Pyrrolo [2, 3-d] pyrimidines qui modulent l'activite ack1 et lck
SE0402735D0 (sv) *	2004-11-09	2004-11-09	Astrazeneca Ab	Novel compounds
KR20070114753A (ko) *	2005-02-18	2007-12-04	아브락시스 바이오사이언스 인크.	치료제의 조합 및 투여 방식, 및 조합 요법
DE102005024157A1 (de)	2005-05-23	2006-11-30	Amedo Gmbh	Nadelpositioniersystem
EP1885716B1 (fr)	2005-05-24	2012-11-07	Merck Serono SA	Derives thiazole et utilisation
UA96735C2 (en)	2005-05-24	2011-12-12	Мерк Сероно Са	Thiazole derivatives and use thereof
DE102005024790A1 (de)	2005-05-26	2006-12-07	Eos Gmbh Electro Optical Systems	Strahlungsheizung zum Heizen des Aufbaumaterials in einer Lasersintervorrichtung
US7655446B2 (en)	2005-06-28	2010-02-02	Vertex Pharmaceuticals Incorporated	Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof
DE102005048072A1 (de)	2005-09-24	2007-04-05	Bayer Cropscience Ag	Thiazole als Fungizide
TW200730476A (en)	2005-12-12	2007-08-16	Genelabs Tech Inc	N-(5-membered aromatic ring)-amido anti-viral compounds
GB0525671D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
JP2009523769A (ja) *	2006-01-23	2009-06-25	ラボラトワールセローノソシエテアノニム	チアゾール誘導体及びこれらの使用
US20070259855A1 (en)	2006-04-06	2007-11-08	Udo Maier	Thiazolyl-dihydro-indazole
US20090076009A1 (en) *	2006-05-03	2009-03-19	Arnould Jean-Claude Retired	Thiazole derivatives and their use as anti-tumour agents
GB0610243D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
GB0612630D0 (en) *	2006-06-26	2006-08-02	Novartis Ag	Organic compounds
FR2904190B1 (fr)	2006-07-25	2008-12-12	Inst Rech Pour Le Dev I R D Et	Utilisation d'inocula fongiques pour l'amelioration de la production maraichere
TW200827368A (en)	2006-11-21	2008-07-01	Genelabs Tech Inc	Amido anti-viral compounds
WO2008124000A2 (fr)	2007-04-02	2008-10-16	Ligand Pharmaceuticals Incorporated	Dérivés de thiazole utilisés comme composés modulateurs de récepteurs d'androgènes
RU2479577C2 (ru)	2007-05-25	2013-04-20	Эбботт Гмбх Унд Ко.Кг	Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2)
WO2009003009A1 (fr)	2007-06-26	2008-12-31	Enanta Pharmaceuticals, Inc.	Pyrrolidine substituée utilisée en tant qu'agent anti-infectieux
HUE026446T2 (en)	2007-07-19	2016-05-30	Lundbeck H As	5-membered heterocyclic amides and related compounds
UY31545A1 (es)	2007-12-20	2009-08-03		Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
JP2011506563A (ja)	2007-12-20	2011-03-03	ノバルティスアーゲー	ビスチアゾール誘導体、その製造方法および医薬品としてのその使用
ITMI20072396A1 (it)	2007-12-20	2009-06-21	Dachi S R L	"apparato di chiusura di contenitori di materiale biologico"
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

2009
- 2009-08-09 UA UAA201102837A patent/UA104147C2/uk unknown
- 2009-09-08 PT PT97827778T patent/PT2331537E/pt unknown
- 2009-09-08 EA EA201100447A patent/EA018863B1/ru active Protection Beyond IP Right Term
- 2009-09-08 UY UY0001032096A patent/UY32096A/es active IP Right Grant
- 2009-09-08 MX MX2011002597A patent/MX2011002597A/es active IP Right Grant
- 2009-09-08 MY MYPI20110510 patent/MY151556A/en unknown
- 2009-09-08 SI SI200931344T patent/SI2331537T1/sl unknown
- 2009-09-08 PL PL09782777T patent/PL2331537T3/pl unknown
- 2009-09-08 HR HRP20160014TT patent/HRP20160014T1/hr unknown
- 2009-09-08 ME MEP-2011-21A patent/ME01284B/fr unknown
- 2009-09-08 RS RS20150860A patent/RS54476B1/sr unknown
- 2009-09-08 DK DK09782777.8T patent/DK2331537T3/en active
- 2009-09-08 CN CN200980135415.7A patent/CN102149711B/zh active Active
- 2009-09-08 BR BRPI0918750A patent/BRPI0918750B8/pt active IP Right Grant
- 2009-09-08 EP EP09782777.8A patent/EP2331537B1/fr active Active
- 2009-09-08 AR ARP090103437A patent/AR073369A1/es not_active Application Discontinuation
- 2009-09-08 WO PCT/EP2009/061644 patent/WO2010029082A1/fr not_active Ceased
- 2009-09-08 GE GEAP200912132A patent/GEP20135991B/en unknown
- 2009-09-08 HU HUE09782777A patent/HUE025884T2/en unknown
- 2009-09-08 CA CA2734819A patent/CA2734819C/fr active Active
- 2009-09-08 ES ES09782777.8T patent/ES2560673T3/es active Active
- 2009-09-08 KR KR1020117005524A patent/KR101290844B1/ko active Active
- 2009-09-08 NZ NZ590754A patent/NZ590754A/xx unknown
- 2009-09-08 AU AU2009290904A patent/AU2009290904B2/en active Active
- 2009-09-08 PE PE2011000591A patent/PE20110796A1/es active IP Right Grant
- 2009-09-08 JP JP2011526479A patent/JP5486601B2/ja active Active
- 2009-09-09 JO JOP/2009/0334A patent/JO3121B1/ar active
- 2009-09-09 TW TW098130412A patent/TWI453206B/zh active
- 2009-09-10 US US12/556,964 patent/US8227462B2/en active Active
- 2009-09-10 PA PA20098841901A patent/PA8841901A1/es unknown
2011
- 2011-01-27 ZA ZA2011/00699A patent/ZA201100699B/en unknown
- 2011-01-31 IL IL210976A patent/IL210976A/en active IP Right Grant
- 2011-01-31 TN TN2011000053A patent/TN2011000053A1/fr unknown
- 2011-02-01 CR CR20110059A patent/CR20110059A/es unknown
- 2011-03-01 MA MA33661A patent/MA32604B1/fr unknown
- 2011-03-07 DO DO2011000070A patent/DOP2011000070A/es unknown
- 2011-03-08 HN HN2011000699A patent/HN2011000699A/es unknown
- 2011-03-09 CL CL2011000504A patent/CL2011000504A1/es unknown
- 2011-03-09 NI NI201100049A patent/NI201100049A/es unknown
- 2011-03-10 CU CU2011000052A patent/CU24000B1/es active IP Right Grant
- 2011-03-10 EC EC2011010880A patent/ECSP11010880A/es unknown
- 2011-03-10 SV SV2011003853A patent/SV2011003853A/es unknown
- 2011-03-17 CO CO11033546A patent/CO6351738A2/es active IP Right Grant
- 2011-04-07 SM SM201100019T patent/SMP201100019B/it unknown
2012
- 2012-06-05 US US13/488,589 patent/US8476268B2/en active Active
2013
- 2013-05-24 US US13/901,930 patent/US8710085B2/en active Active
2014
- 2014-02-27 US US14/192,633 patent/US20140186469A1/en not_active Abandoned
2015
- 2015-12-29 CY CY20151101197T patent/CY1117078T1/el unknown
2018
- 2018-06-06 AR ARP180101520A patent/AR112074A2/es not_active Application Discontinuation
2020
- 2020-11-06 NL NL301071C patent/NL301071I2/nl unknown
- 2020-11-16 NO NO2020037C patent/NO2020037I1/no unknown
- 2020-11-18 HU HUS2000044C patent/HUS2000044I1/hu unknown
- 2020-11-20 LU LU00186C patent/LUC00186I2/fr unknown
- 2020-11-24 CY CY2020037C patent/CY2020037I2/el unknown
- 2020-11-25 LT LTPA2020534C patent/LTC2331537I2/lt unknown
- 2020-11-26 FI FIC20200046C patent/FIC20200046I1/fi unknown

Also Published As

Publication number	Publication date
JP5486601B2 (ja)	2014-05-07
SMAP201100019A (it)	2011-05-06
US20120263712A1 (en)	2012-10-18
MY151556A (en)	2014-06-13
PT2331537E (pt)	2016-03-03
US8476268B2 (en)	2013-07-02
GEP20135991B (en)	2013-12-25
DOP2011000070A (es)	2011-03-31
TW201014851A (en)	2010-04-16
PL2331537T3 (pl)	2016-06-30
NL301071I2 (nl)	2020-12-01
LTC2331537I2 (lt)	2022-01-10
EA201100447A1 (ru)	2011-10-31
HUS2000044I1 (hu)	2020-12-28
SI2331537T1 (sl)	2016-02-29
NO2020037I1 (no)	2020-11-16
AR073369A1 (es)	2010-11-03
ZA201100699B (en)	2012-08-29
CA2734819A1 (fr)	2010-03-18
CY1117078T1 (el)	2017-04-05
SV2011003853A (es)	2011-05-16
CL2011000504A1 (es)	2011-07-15
FIC20200046I1 (fi)	2020-11-26
EP2331537A1 (fr)	2011-06-15
NZ590754A (en)	2012-08-31
JP2012502080A (ja)	2012-01-26
MX2011002597A (es)	2011-07-21
PA8841901A1 (es)	2010-06-28
CO6351738A2 (es)	2011-12-20
JO3121B1 (ar)	2017-09-20
US20140005232A1 (en)	2014-01-02
LTPA2020534I1 (lt)	2020-12-28
NL301071I1 (nl)	2020-11-11
HUE025884T2 (en)	2016-05-30
CU24000B1 (es)	2014-06-27
AU2009290904B2 (en)	2012-08-30
US20100105711A1 (en)	2010-04-29
US8227462B2 (en)	2012-07-24
LUC00186I2 (fr)	2024-07-01
NI201100049A (es)	2011-07-26
BRPI0918750B1 (pt)	2020-12-22
BRPI0918750B8 (pt)	2021-05-25
EA018863B1 (ru)	2013-11-29
DK2331537T3 (en)	2016-01-25
KR20110038737A (ko)	2011-04-14
CU20110052A7 (es)	2011-12-28
MA32604B1 (fr)	2011-09-01
CN102149711A (zh)	2011-08-10
WO2010029082A1 (fr)	2010-03-18
AU2009290904A1 (en)	2010-03-18
HK1156305A1 (en)	2012-06-08
HRP20160014T1 (hr)	2016-02-12
PE20110796A1 (es)	2011-11-04
CR20110059A (es)	2011-03-28
RS54476B1 (sr)	2016-06-30
CN102149711B (zh)	2014-09-10
ES2560673T3 (es)	2016-02-22
HN2011000699A (es)	2013-12-02
SMP201100019B (it)	2012-01-18
EP2331537B1 (fr)	2015-10-28
ME01284B (fr)	2013-06-20
TWI453206B (zh)	2014-09-21
US20140186469A1 (en)	2014-07-03
CA2734819C (fr)	2017-10-24
UY32096A (es)	2010-04-30
BRPI0918750A2 (pt)	2020-08-04
US8710085B2 (en)	2014-04-29
ECSP11010880A (es)	2011-04-29
KR101290844B1 (ko)	2013-07-29
UA104147C2 (uk)	2014-01-10
AR112074A2 (es)	2019-09-18
IL210976A (en)	2014-09-30
CY2020037I1 (el)	2021-03-12
IL210976A0 (en)	2011-04-28
CY2020037I2 (el)	2021-03-12

Publication	Publication Date	Title
TN2011000053A1 (en)	2012-09-05	Organic compounds
TN2010000293A1 (en)	2011-11-11	Thiazole derivatives used as pi 3 kinase inhibitors
MX2012000177A (es)	2012-02-28	2-carboxamida-cicloamino-ureas sustituidas.
TN2010000038A1 (en)	2011-09-26	Organic compounds
EP3586631A3 (fr)	2020-03-18	Composition pour la santé des plantes
NZ597517A (en)	2014-04-30	5-fluoropyrimidinone derivatives
PH12015501585A1 (en)	2015-09-21	Manufacturing process for pyrimidine derivatives
UA107445C2 (uk)	2015-01-12	5-фторпіримідинові похідні як фунгіциди
WO2009080705A3 (fr)	2009-09-24	Composés organiques
MY164776A (en)	2018-01-30	Heterocyclic compound
MX2010004493A (es)	2010-06-11	Compuestos de tropano.
NZ597570A (en)	2014-04-30	N1-acyl-5-fluoropyrimidinone derivatives
WO2011047055A3 (fr)	2011-08-18	Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
MX2008016358A (es)	2009-01-16	Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
MX2012000178A (es)	2012-02-28	2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
MX2013002620A (es)	2013-05-09	Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
JO2999B1 (ar)	2016-09-05	مركب ثلاثي حلقي و استخدامه الدوائي
NZ591837A (en)	2013-03-28	Amino acid derivative
DE602008002598D1 (en)	2010-10-28	Cyclohexylderivate
GB0602951D0 (en)	2006-03-29	Organic Compounds
NZ590076A (en)	2012-11-30	Treating plexiform neurofibroma and related tumors
NZ599916A (en)	2013-10-25	5-amino-4-hydroxypentoyl amides
ATE522530T1 (de)	2011-09-15	2-piperazin-1-yl-3h-imidazoä4,5-bü- pyridinderivate
MX2011012511A (es)	2012-02-28	Anti-oomicetos.